TACLONEX SUMMARY
Taclonex® Ointment contains calcipotriene hydrate and betamethasone dipropionate. It is intended for topical use.
Calcipotriene hydrate is a synthetic vitamin D3 analogue.
Betamethasone dipropionate is a synthetic corticosteroid.
Each gram of Taclonex® Ointment contains 52.18 mcg of calcipotriene hydrate (equivalent to 50 mcg of calcipotriene) and 0.643 mg of betamethasone dipropionate (equivalent to 0.5 mg of betamethasone) in an ointment base of mineral oil, PPG-15 stearyl ether, dl-alpha tocopherol and white petrolatum.
Taclonex® Ointment is indicated for the topical treatment of psoriasis vulgaris in adults 18 years of age and above for up to 4 weeks. The maximum weekly dose should not exceed 100 g. Treatment of more than 30% body surface area is not recommended.
Taclonex® Ointment should not be applied to the face, axillae or groin.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Taclonex (Calcipotriene / Betamethasone Topical)
Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris. [2010.08]
The two-compound ointment (Taclonex/Daivobet/Dovobet ointment) combining calcipotriene 50 microg/g and betamethasone 0.5 mg/g (as dipropionate) is very effective in the treatment of psoriasis vulgaris... No patients using the two-compound ointment for all 52 weeks or alternating four-weekly with calcipotriene had HPA axis suppression.
A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. [2006.10]
BACKGROUND: The merit of topical sequential therapy involving clobetasol foam and calcipotriene ointment has not been experimentally demonstrated. OBJECTIVE: We sought to assess the short-term efficacy of twice-daily clobetasol foam plus calcipotriene ointment compared with either agent alone as monotherapy and to compare long-term use of weekday calcipotriene ointment with or without clobetasol foam weekend pulse therapy... CONCLUSION: The combination of clobetasol foam and calcipotriene ointment is significantly more effective than monotherapy for short-term treatment. Weekday calcipotriene plus weekend pulse clobetasol foam shows a consistent trend toward greater maintenance of remission.
A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. [2006.06]
BACKGROUND: The calcipotriol/betamethasone dipropionate two-compound product Dovobet/Daivobet/Taclonex(LEO Pharma A/S, Ballerup, Denmark) has been shown to be safe and effective in the treatment of psoriasis for up to 8 weeks. As psoriasis is a chronic disease, long-term treatment may be required, so there is a need to investigate the safety of its use over a longer period of time. OBJECTIVES: To investigate the safety of two treatment regimens involving use of the two-compound product over 52 weeks in the treatment of patients with psoriasis... CONCLUSIONS: Treatment with the two-compound product for up to 52 weeks appears to be safe and well tolerated whether used on its own or alternating every 4 weeks with calcipotriol treatment.
Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. [2006]
BACKGROUND: The calcipotriol/betamethasone dipropionate two-compound product is safe and effective in the short-term treatment of psoriasis. OBJECTIVE: The primary objective was to investigate the safety of two treatment regimens involving use of the two-compound product over 52 weeks. The efficacy results are presented here... CONCLUSION: There was a trend towards the efficacy of the two-compound product used for up to 52 weeks being better than that of 4 weeks of the two-compound product followed by 48 weeks of calcipotriol. Copyright (c) 2006 S. Karger AG, Basel.
Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial. [2006]
INTRODUCTION: A calcipotriene/betamethasone dipropionate two-compound product (Taclonex ointment) has been shown to be safe and effective in the treatment of psoriasis over 4 weeks. Since treatment of psoriasis is generally long-term, the objective of this study was to investigate the efficacy and safety of transferring patients to maintenance treatment with calcipotriene cream (Dovonex cream) following a 4-week treatment period with the two-compound product... CONCLUSION: Four weeks of treatment with the calcipotriene/betamethasone dipropionate two-compound product followed by 8 weeks of maintenance treatment with calcipotriene cream is effective and safe. As an alternative maintenance regimen, treatment with calcipotriene cream on weekdays and the two-compound product on weekends is also effective and safe.
Clinical Trials Related to Taclonex (Calcipotriene / Betamethasone Topical)
Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris [Active, not recruiting]
This is an open label, investigator-blinded, cross over, prospective, single center study of
subjects with plaque psoriasis. Taclonex® (calcipotriene 0. 005% and betamethasone
dipropionate 0. 064%) Ointment and Taclonex Scalp® (calcipotriene 0. 005% and betamethasone
dipropionate 0. 064%) Topical Suspension will each be applied topically once daily.
The primary objective is to assess the patient preference for Taclonex® (calcipotriene
0. 005% and betamethasone dipropionate 0. 064%) Ointment compared to Taclonex Scalp®
(calcipotriene 0. 005% and betamethasone dipropionate 0. 064%) Topical Suspension in the
treatment of plaque psoriasis.
The secondary objective is to assess the efficacy for Taclonex® (calcipotriene 0. 005% and
betamethasone dipropionate 0. 064%) Ointment compared to Taclonex Scalp® (calcipotriene
0. 005% and betamethasone dipropionate 0. 064%) Topical Suspension in the treatment of plaque
psoriasis.
Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis [Completed]
The purpose of this study is to determine whether using Taclonex ointment under a hydrogel
patch is more effective than using the ointment alone in treating psoriasis. Taclonex
ointment is currently FDA approved for use on psoriasis. The hydrogel patch is a type of
adhesive pad and contains no medications. It is currently FDA approved and has been shown to
be safe and virtually free of side effects. The hypothesis is that psoriatic plaques which
are treated with Taclonex ointment under a hydrogel patch will be more effectively treated
compared to psoriatic plaques treated with Taclonex alone.
A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy [Recruiting]
Oral therapies for psoriasis, including methotrexate and acitretin, are often less effective
when used as monotherapy (without other oral medicines or creams) than are newer biologic
injected drugs. However, these oral medications are also less expensive than biologic agents
and may be safer for use in some patients. The purpose of this study is to determine if
adding a topical psoriasis medicine, Taclonex topical suspension, will improve the severity
of psoriasis in patients already on methotrexate or acitretin and to determine if adding
this topical suspension will reduce the desire of such patients to switch to a biologic
agent to treat their psoriasis.
Efficacy, Safety, Preference and Response Duration of Clobex� Spray and Taclonex� Ointment in Psoriasis [Completed]
Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva) [Terminated]
The purpose of this study is to determine if calcipotriene/bethamethasone can safely and
effectively manage the occurence of LMB (mild localized breakthrough) in patients recieving
efalizumab (Raptiva) for moderate to severe plaque psoriasis.
It is hypothesized that calcipotriene/betamethasone (Taclonex) could be used to manage LMB
and thus allow patients to continue efalizumab without interruption.
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Taclonex has an overall score of 10. The effectiveness score is 10 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
| | Taclonex review by 32 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Highly Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | Psoriasis |
| Dosage & duration: | | Pea size to skin effected (dosage frequency: daily in the evening) for the period of 4 weeks |
| Other conditions: | | none |
| Other drugs taken: | | lexapro 10 mg | | |
Reported Results |
| Benefits: | | this was the only ointment that improved my psoriasis. I applied the ointment to my patches of psoriasis and felt immediate relief of the burning and itching associated with psoriasis |
| Side effects: | | none at this time. |
| Comments: | | apply ointment to areas of skin before bed - use sparingly a small dab rubbed into the scales works wonders |
|
|
|
Page last updated: 2010-10-05
|
